A. Legal Requirement, Guidance for the Notification of Serious Breaches of GCP or the Trial Protocol Version 6, 08 Jul 2020, MHRA

Regulation 29A of the Medicines for Human Use (Clinical Trials) Regulations 2004 [Statutory Instrument 2004/1031], as amended by Statutory Instrument 2006/1928, contains a requirement for the notification of “serious breaches” of GCP or the trial protocol:

“29A. (1) The sponsor of a clinical trial shall notify the licensing authority in writing of any serious breach of –

(a) the conditions and principles of GCP in connection with that trial; or

(b) the protocol relating to that trial, as amended from time to time in accordance with regulations 22 to 25, within 7 days of becoming aware of that breach.

(2) For the purposes of this regulation, a “serious breach” is a breach which is likely to effect to a significant degree –

(a) the safety or physical or mental integrity of the subjects of the trial; or

(b) the scientific value of the trial”.

 

Back to the index of the Guidance for the Notification of Serious Breaches of GCP or the Trial Protocol Version 6, 08 Jul 2020, MHRA, Medicines & Healthcare products Regulatory Agency

Clinical Research News

First AI-Designed Vaccine Completes Human Trials
Blood in Urine and Suspected Tumor: New Urine Test to be Compared Against Cystoscopy and Biopsy
When Ultrasound Shows an Anomaly but Genetics Are Silent: Whole-Genome Gequencing (WGS) Put to the Test
Chronic Pancreatitis and Cancer Risk: Scientists Look to the Immune System for Early Clues
Protecting the Heart Before Going Home: Hospitals Test Giving Flu Shots Right Before Discharge
High Cholesterol: New Non-Statin Drug to Be Compared Directly With Bempedoic Acid
Delivering Radiation Straight to the Tumor: New Prostate Cancer Trial Begins

Bevorstehende klinische Studien

Clinical Research Jobs

More jobs

Sponsoren und Mitarbeiter

Krankheiten

Drogeninterventionen

Abonnieren